Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 2/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL806095 | 0.91 | TSHR (0.33) | USP2CYP3A4MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL16418495 | 0.83 | MAPT (0.47) | USP2CYP3A4MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL16421121 | 0.83 | MAPT (0.47) | USP2CYP3A4MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL27163466 | 0.81 | MAPT (0.38) | USP2CYP3A4MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL2221417 | 0.80 | MAPT (0.44) | USP2CYP3A4MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL2221420 | 0.80 | MAPT (0.44) | USP2CYP3A4MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL7914583 | 0.80 | MAPT (0.44) | USP2CYP3A4MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL11066540 | 0.79 | LMNA (0.35) | USP2CYP3A4MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL29277716 | 0.76 | CA2 (0.43) | USP2CYP3A4MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL27810719 | 0.76 | MAPT (0.40) | USP2CYP3A4MAPTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120094897-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094897-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| WO-2012037259-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094897-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HDGF | USP2 1172/4885CYP3A4 2025/4885MAPT 4380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.